Literature DB >> 23450408

[Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru].

Jorge Alave1, Jorge Paz, Elsa González, Miguel Campos, Martin Rodríguez, James Willig, Juan Echevarría.   

Abstract

OBJECTIVE: To describe clinical and biological characteristics of subjects with virologic failure who participated in the sexually transmitted diseases HIV/AIDS National Program from a Peruvian public hospital.
MATERIALS AND METHODS: An exploratory descriptive study was performed with data from subjects older than 18 who started high activity antiretroviral therapy (HAART) between May 2004 and December 2009 and who had a viral load control after 24 weeks of HAART. Virologic failure was defined as a viral load value above 1000 copies/mL on follow up after 24 weeks on HAART.
RESULTS: Of 1478 records of patients on HAART analyzed, the median age was 35 years [IQR, 29-41] and 69.6% were male. Also, virologic failure occurred in 24% and 3.7% died. Of subjects with virologic failure, 9.5% died. On multivariate analysis, age, history of antiretroviral use before starting HAART, change of antiretroviral therapy due to toxicity, opportunistic infections during HAART, level of CD4 + lymphocytes below 100 cells/ml at start of HAART, adherence and clinical stage were independently associated with virologic failure. In the group of patient with no history of antiretroviral use before starting HAART, age, opportunistic infections during HAART were associated with virologic failure.
CONCLUSION: This study identified factors associated with virologic failure. Further studies are needed to evaluate whether the use of these factors can help to identify prospectively patients at high risk of failure, and to design interventions aimed to reduce this risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23450408      PMCID: PMC3892375          DOI: 10.4067/S0716-10182013000100006

Source DB:  PubMed          Journal:  Rev Chilena Infectol        ISSN: 0716-1018            Impact factor:   0.520


  29 in total

Review 1.  [Predictive factors of virological response to primary antiretroviral treatment].

Authors:  J-F Faucher; B Challier; C Chirouze; C Drobacheff; P Fischer; J-M Lang; L Boyer; T May; M Froidure; P Chavanet; F-X Lescure; C Strady; B Hoen
Journal:  Presse Med       Date:  2004-03-13       Impact factor: 1.228

2.  Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis.

Authors:  Pythia T Nieuwkerk; Frans J Oort
Journal:  J Acquir Immune Defic Syndr       Date:  2005-04-01       Impact factor: 3.731

3.  Rate and predictors of optimal virologic response to antiretroviral therapy in Colombia.

Authors:  Carlos A Diazgranados; Alfonso Silva; Adriana Bermudez; Diana Roncancio; Pierina Diruggiero; Monica Mantilla
Journal:  Int J Infect Dis       Date:  2007-05-23       Impact factor: 3.623

4.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

Authors:  S G Deeks; F M Hecht; M Swanson; T Elbeik; R Loftus; P T Cohen; R M Grant
Journal:  AIDS       Date:  1999-04-16       Impact factor: 4.177

5.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; M Opravil; A Telenti; B Hirschel; M Battegay; P Vernazza; P Sudre; M Flepp; H Furrer; P Francioli; R Weber
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

6.  Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance.

Authors:  Javier R Lama; Jorge Sanchez; Luis Suarez; Patricia Caballero; Alberto Laguna; Jose L Sanchez; William L H Whittington; Connie Celum; Robert M Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-01       Impact factor: 3.731

7.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification.

Authors:  Maya L Petersen; Mark J van der Laan; Sonia Napravnik; Joseph J Eron; Richard D Moore; Steven G Deeks
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

8.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Authors:  Jean-Jacques Parienti; Véronique Massari; Diane Descamps; Astrid Vabret; Elisabeth Bouvet; Bernard Larouzé; Renaud Verdon
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

9.  Older age and the response to and tolerability of antiretroviral therapy.

Authors:  Michael J Silverberg; Wendy Leyden; Michael A Horberg; Gerald N DeLorenze; Daniel Klein; Charles P Quesenberry
Journal:  Arch Intern Med       Date:  2007-04-09

10.  British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

Authors:  Ian Williams; Duncan Churchill; Jane Anderson; Marta Boffito; Mark Bower; Gus Cairns; Kate Cwynarski; Simon Edwards; Sarah Fidler; Martin Fisher; Andrew Freedman; Anna Maria Geretti; Yvonne Gilleece; Rob Horne; Margaret Johnson; Saye Khoo; Clifford Leen; Neal Marshall; Mark Nelson; Chloe Orkin; Nicholas Paton; Andrew Phillips; Frank Post; Anton Pozniak; Caroline Sabin; Roy Trevelion; Andrew Ustianowski; John Walsh; Laura Waters; Edmund Wilkins; Alan Winston; Mike Youle
Journal:  HIV Med       Date:  2012-09       Impact factor: 3.180

View more
  15 in total

1.  Prevalence and Predictors of Virological Failure Among Adults Living with HIV in South Wollo Zone, Northeast Ethiopia: A Retrospective Cohort Study.

Authors:  Teklehaimanot Fentie Wendie; Birhanu Demeke Workneh
Journal:  HIV AIDS (Auckl)       Date:  2020-09-07

2.  Virological and Immunological Antiretroviral Treatment Failure and Predictors Among HIV Positive Adult and Adolescent Clients in Southeast Ethiopia.

Authors:  Ayele Mamo; Tesfaye Assefa; Wegene Negash; Yohannes Takelign; Biniyam Sahiledinigl; Zinash Teferu; Mesud Mohammed; Damtew Solomon; Habtamu Gezahegn; Kebebe Bekele; Demsu Zenbaba; Alelign Tasew; Anwar Tahir; Fikereab Desta; Tadele Regassa; Abule Takele; Zegeye Regassa; Daniel Atilaw
Journal:  HIV AIDS (Auckl)       Date:  2022-02-26

3.  Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network.

Authors:  Marcelo Wolff; Bryan E Shepherd; Claudia Cortés; Peter Rebeiro; Carina Cesar; Sandra Wagner Cardoso; Jean W Pape; Denis Padgett; Juan Sierra-Madero; Juan Echevarria; Catherine C McGowan
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

4.  Unsuppressed Viral Load Level in Public Health Facilities: Nonvirological Predictors among Adult Antiretroviral Therapy Users in Southwestern Ethiopia.

Authors:  Birhanu Waju; Lamessa Dube; Muktar Ahmed; Semira Shimeles Assefa
Journal:  HIV AIDS (Auckl)       Date:  2021-05-14

5.  Modeling Outcomes of First-Line Antiretroviral Therapy and Rate of CD4 Counts Change among a Cohort of HIV/AIDS Patients in Ethiopia: A Retrospective Cohort Study.

Authors:  Tadesse Awoke; Alemayehu Worku; Yigzaw Kebede; Adetayo Kasim; Belay Birlie; Roel Braekers; Khangelani Zuma; Ziv Shkedy
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

6.  Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: Systematic review and meta-analysis.

Authors:  Jessica de Mattos Costa; Thiago Silva Torres; Lara Esteves Coelho; Paula Mendes Luz
Journal:  J Int AIDS Soc       Date:  2018-01       Impact factor: 5.396

7.  Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes.

Authors:  Phirum Lay; Sokkab An; Sunpiseth Soeung; Pich Sovannary Srey; Sopheak Thai; Lutgarde Lynen; Johan van Griensven
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

8.  Increased Virological Failure and Determinants Among HIV Patients on Highly Active Retroviral Therapy in Adigrat General Hospital, Northern Ethiopia, 2019: Hospital-Based Cross-Sectional Study.

Authors:  Hadush Negash; Miglas Welay; Haftom Legese; Gebre Adhanom; Fitsum Mardu; Kebede Tesfay; Aderajew Gebrewahd; Brhane Berhe
Journal:  Infect Drug Resist       Date:  2020-06-18       Impact factor: 4.003

9.  Use of third line antiretroviral therapy in Latin America.

Authors:  Carina Cesar; Bryan E Shepherd; Cathy A Jenkins; Massimo Ghidinelli; Jose Luis Castro; Valdiléa Gonçalves Veloso; Claudia P Cortes; Denis Padgett; Brenda Crabtree-Ramirez; Eduardo Gotuzzo; Valeria Fink; Adriana Duran; Omar Sued; Catherine C McGowan; Pedro Cahn
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

10.  Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia.

Authors:  Genet Gebrehiwet Hailu; Dawit Gebregziabher Hagos; Amlsha Kahsay Hagos; Araya Gebreyesus Wasihun; Tsehaye Asmelash Dejene
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.